2022 journal article

Novel subcutaneous cytarabine infusion with the Omnipod system in dogs with meningoencephalomyelitis of unknown etiology


By: S. Mancini n, P. Early n, B. Slater n, N. Olby n, C. Mariani n, K. Munana n, C. Woelfel n, J. Schacher n, L. Zhong n, K. Messenger n

MeSH headings : Animals; Area Under Curve; Chromatography, High Pressure Liquid / veterinary; Cytarabine / therapeutic use; Dogs; Half-Life; Humans; Infusions, Intravenous / veterinary; North Carolina
TL;DR: An SC continuous-rate infusion of cytarabine via the Omnipod system is feasible in dogs and was able to achieve a steady-state concentration of more than 1 μg/mL 4 to 10 hours postinitiation of cyTarabine and a Cmax of 7,510 ng/mL, comparable to values reported previously with IV continuous- rate infusion administration in healthy research Beagles and dogs with meningoencephalomyelitis of unknown etiology. (via Semantic Scholar)
Source: Web Of Science
Added: August 1, 2022